This is an interesting report insofar as it quotes, not from VLA's Board press releases, but directly from Malcolm's investor briefing. It seems Bioshares are still bullish on the story.
A couple of quotes stood out for me;
"Viralytics has achieved startling results in mice... when combining Cavatak with an anti-PD1 compound..." Words like startling appeal to me when used in science.
"Intravenous trials with Amgen’s T-Vec have not been conducted, possibly because T-Vec is a large envelope virus and is quickly mopped up by the innate immune system..."
"the company’s overseas institutional investors remain bemused at Viralytics’ market value of $57 million..."
I bet they're bemused. Bemused enough to increase their stake at apparently unbelievable prices?? I wish...
VLA Price at posting:
30.5¢ Sentiment: Buy Disclosure: Held